A St. Louis, Missouri medical device company is raising money in preparation for clinical trials of its pain-free cardioversion therapy for atrial fibrillation, developed by a former Case Western Reserve University researcher.
CardiaLen Inc. has secured $2.4 million for its implantable low-voltage atrial cardioverter, technology developed by Prof. Igor Efimov and licensed from Washington University and Case.
Atrial fibrillation is the most common form of cardiac arrhythmia and increases a person’s risk for stroke and premature death. Since patients typically remain conscious during episodes, a pain-free operation is essential to AF treatment, according to CardiaLen.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Founded in 2008, CardiaLen has facilitated the development of its technology by raising more than $1.2 million in seed capital in 2009 and 2010. It also raised $1.1 million from Broadview Ventures in 2011 and more than $450,000 in government grants. Other investors include St. Louis Arch Angels and BIOGenerator.
CardiaLen operates its clinical headquarters in St. Louis and operates a production facility in St. Paul, Minnesota. A phone message to CEO Bob Calcaterra seeking more information was not returned.